Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Go back to Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 80.67 +2.85 (3.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $77.82 | 52 Week High | $18.39 | |||
| Open | $77.43 | 52 Week Low | $6.96 | |||
| Day High | $81.05 | P/E | N/A | |||
| Day Low | $76.82 | EPS | $-0.58 | |||
| Volume | 866,142 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.15 +0.36 (0.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.79 | 52 Week High | $118.49 | |||
| Open | $115.04 | 52 Week Low | $55.00 | |||
| Day High | $117.47 | P/E | N/A | |||
| Day Low | $114.51 | EPS | $-0.56 | |||
| Volume | 398,046 | |||||
